Medical management of clomiphene-resistant polycystic ovarian syndrome: an update
Keywords:
PCOS, Infertility, Clomiphene citrate resistance, DrugsAbstract
Clomiphene citrate is the traditional first-line treatment for chronic anovulation that characterizes polycystic ovary syndrome (PCOS). A gold standard therapy has always been Clomiphene Citrate (CC). However, 20%-25% of PCOS women fail to ovulate with incremental doses of CC. A good body of evidence suggest that alternatives for PCOS women with CC-resistant anovulation include insulin sensitizers like metformin and pioglitazone. Insulin sensitizers improves pregnancy outcome and ovulation rate by and acts by ameliorating insulin sensitivity and hyperandrogenemia. Metformin is preferred in obese women. Gonadotropins induce ovulation and maintain optimal follicle growth via controlled administration of follicle stimulation hormone. Two regimens are used which includes high and low dose regimen. Low dose regimen is preferred but is associated adverse effects like ovarian hyperstimulation syndrome (OHSS) and increased cost. Extending clomiphene therapy reduces cost and improves pregnancy outcome. Glucocorticoids are preferably used when serum Dehydroepiandrosterone levels are > 200µg/dL. Bromocriptine improves ovulation rate by decreasing prolactin levels. Human Chorionic Gonadotropin restores ovulation but its use is limited during intrauterine insemination. Tamoxifen acts in a similar way as CC but has lesser antiestrogenic effect on the endometrium, cervical mucus, and granulosa cells, hence an added advantage of monofollicular ovulation. Aromatase inhibitors block conversion androstenedione and testosterone to estrogen in ovary and improves ovulation rate. Added advantage includes lesser cost, simple to use, no danger of multiple pregnancies and convenient for patient. Combination of GnRH analogues and Gonadotropins are associated with increased risk of OHSS. D-chiro-inositol, N-Acetylcysteine, melatonin and acarbose are tried with little success.
Metrics
References
Balen A. H., The current understanding of polycystic ovary syndrome. Obstet Gynaecol. 2004;6:66-74.
Diamanti-Kandarkis E. Polycystic ovarian syndrome pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:1-21.
Schuring AN., Schulte N., Sonntag B., Kiesel L. Androgens and insulin-two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch. 2008;48:9-15.
Fulghesu AM., Ciampelli M., Muzj G., Belosi C., Selvaggi L., Ayala GF., Lanzone A.N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steri. 2002;77:1128-35.
Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse EW, Prelevic GM. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:4496-4501.
Ketel IJ., Stehouwer CD., Serné EH., Korsen TJ., Hompes PG., Smulders YM., de Jongh RT., Homburg R., Lambalk CB.. Obese but not normal weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008;93:3365-72.
Pasquali R., Pelusi C., Genghini S., Cacciari M., Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9:359–72.
Moran LJ., Noakes M., Clifton PM., Tomlinson L., Galletly C., Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:812–9.
Kiddy DS., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed MJ., Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992;36:105–11.
Yanovski S Z and Yanovski JA. Obesity. N Engl J Med. 2002;346:591–602.
Norman RJ., Davies MJ., Lord J. & Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends in Endocrinology and Metabolism. 2002Aug;13(6):251-7.
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505–22.
Dickey RP., Taylor SN., Curole DN., Rye PH., Pyrzak R. Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod. 1996Dec;11(12):2623–8.
Westhoff CL., Scoccia B., Lamb EL., Lubin JH., Brinton LA. Uterine Cancer after Use of Clomiphene Citrate to Induce Ovulation. Am J Epidemiol. 2005;161:607-15.
Zakherah M S., Nasr A., Saman A M E., Shaaban O M., Shahin A Y. CC plus tamoxifen versus laparoscopic ovarian drilling in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2010;108:240–3.
Legro, RS Castracane, VD. & Kauffman, RP. Detecting insulin resistance in polycystic ovary syndrome purposes and pitfalls. Obstetrical and Gynecological Survey. 2004;59:141–54.
Kowalska I., Kinalski M., Straczkowski M., Wolczyski S., Kinalska I. Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2001;144:509-15.
Batukan C., Baysal B., Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2001;265:124-7.
Heard M J., Pierce A., Carson SA., Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril. 2002;77:669-73.
Vandermolen DT., Ratts VS., Evans WS. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;752:310-5.
Glueck CJ., Wang P., Kobayashi S., Phillips H., Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77:520-5.
Legro RS., Barnhart HX., Schlaff WD., Carr BR., Diamond MP. , Carson SA. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551– 66.
Moll E., Bossuyt PM., Korevaar JC., Lambalk CB., Van D V. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome randomised double blind clinical trial. BMJ. 2006;332:1485–90.
Ortega-Gonzalez C., Luna S., Hernandez L., Crespo G., Aguayo P., Arteaga- Troncoso G. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1360–5.
Ota H., Goto T., Yosioka T., Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008;90:709-1.
Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and CC versus metformin and CC in women with CC-resistant polycystic ovary syndrome. Fertil Steril. 2008;85:428-35.
Badaway A., Elanshar A. Treatment options for PCOS syndrome. Int J Womens Health. 2001;3:25-35.
Christin-Maitre S., Hugues J N. Recominary FSH study group. A comparative randomized multicentric study comparing the step up versus step down protocol in polycystic ovary syndrome. Hum Reprod. 2003;18:1626-31.
Homburg R, Howles CM. Low dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome rational, results, reflections and refinements. Hum repro update. 1999;5:493-9.
Rashidi BH., Gharai M., Momeni M., Tehraninejad ES. A comparision of CC and sequential CC plus human menopausal gondaotropins for use in conjugation with intrauterine insemination. Acta Medica Iranicaa. 2005;433:187-92.
Bayram N., Van Wely M., Van der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2001;2:CD002121. DOI 10.1002/14651858.CD002121.
Spadoni, L., R, Cox, W., and Smith. C. Use of human Menopausal Gonadotropin for the induction of ovulation. Am J Obstet Gynecol. 1986;120:988-1001.
Isaacs JD., Lincoln SR., Cowan BD. Extended CC CC and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril. 1997;67:641-3.
Badawy A., Allam A., Abulatta M. Extending clomiphene treatment in clomiphene-resistant women with PCOS a randomized controlled trial. Reprod Biomed Online. 2008;16: 825-9.
Elnashar A., Abdelmageed E., Fayed M., Sharaf M. CC and dexamethasone in treatment of CC-resistant polycystic ovary syndrome a prospective placebo-controlled study. Hum reprod. 2006;21:1805–8.
Parsanezhad ME., Alborzi S., Rosamsoolat S., Kokabi E. Effect of bromocriptine in polycystic ovarian syndrome with clomiphene citrate resistant. Journal of reproduction and infertility. 2000;1:4-11.
Papaleo, E. Doldi, N. De Santis, L. Marelli, G. Marsiglio, E. Rofena, S. & Ferrari, A. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Human Reproduction. 2001;16:2263-66.
Deaton JL., Clark RR., Pittaway DE., Herbst P., Bauguess P. CC ovulation induction in combination with a timed intrauterine insemination the value of urinary luteinizing hormone versus human chorionic gonadotropin timing. Fertil Steril. 1997;68:43-7.
Zakherah M S., Nasr A., Saman A M E., Shaaban O M., Shahin A Y. CC plus tamoxifen versus laparoscopic ovarian drilling in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2010;108:240–3.
Shahin AY. The problem of IVF cost in developing countries has natural cycle IVF a place? Reprod Biomed Online. 2007;25:1551–6.
Boost Anfor R., Jain JK., Mishell DR., Paulson RJ. A prospective randomized trial comparing CC with tamoxifen citrate for ovulation induction. Fertil Steril. 2001;75:1024-6
Ghafourzadeh M., Karimi M., Karimazadeh M A., Bokai M. Comparison between Two Methods of Ovulation Induction Clomiphene alone and Clomiphene +Tamoxifen in PCOS Patients. IJRM. 2004;2:74-7.
Steiner AZ., Terplan M., Paulson RJ. Comparison of tamoxifen and CC for ovulation induction a metanalysis. Human Reproduction 2005; 1511-5
Casper RF and Mitwally MFM. Casper RF., Mitwally MFM. Casper RF., Mitwally MFM. Review Aromatase Inhibitors for Ovulation Induction. J Clin Endocrinol Metab. 2006;91:760–71.
Barroso G., Menocal G., Felix H., Rojas-Ruiz JC., Arslan M., Oehninger S. Comparison of the efficacy of the aromatase inhibitor letrozole and CC as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation a prospective, randomized, blinded clinical trial. Fertil Steril. 2006;86:1428–31.
Baysoy A., Serdaroglu H., Jamal H., Karatekeli E., Ozornek H., Attar E. Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. Reprod Biomed Online. 2006Aug;13(2):208-12.
Ortmeyer HK., Bodkin NL., Lilley K., Larner J., Hansen BC. Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology. 1993;132:640-5.
Suzuki S, Kawasaki H, Satoh Y, Ohtomo M, Hirai M, Hirai A, Hirai S, Onoda M, Matsumoto M, Hinokio Y. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care. 1994;17:1465-8.
Nestler J., Jakubowicz J., and Iurono J. Role of inositophosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr. Endocrinol Metab. 2000;13Suppl 5:1295-8.
Nestler JE., Jakubowicz DJ., Reamer P., Gunn RD., M.S., Allan G. Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome. New Engl J Med. 1999;340:1314-20.
R Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to CC in CC–resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;83:367-70.
Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, Reiter RJ. Melatonin and the ovary physiological and pathophysiological implications. Fertil Steril. 2009;92:328-43.
Sönmez AS, Yasar L, Savan K, Koc S, Ozcan J, Toklar A. Comparison of the effects of acarbose and metformin use on ovulation rates in CC–resistant polycystic ovary syndrome. Hum Reprod. 2005Jan;20(1):175-9.
